Holz G G, Leech C A, Heller R S, Castonguay M, Habener J F
Diabetes Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
J Biol Chem. 1999 May 14;274(20):14147-56. doi: 10.1074/jbc.274.20.14147.
Glucagon-like peptide-1 (GLP-1) is an intestinally derived insulinotropic hormone currently under investigation for use as a novel therapeutic agent in the treatment of type 2 diabetes mellitus. In vitro studies of pancreatic islets of Langerhans demonstrated that GLP-1 interacts with specific beta-cell G protein-coupled receptors, thereby facilitating insulin exocytosis by raising intracellular levels of cAMP and Ca2+. Here we report that the stimulatory influence of GLP-1 on Ca2+ signaling results, in part, from cAMP-dependent mobilization of ryanodine-sensitive Ca2+ stores. Studies of human, rat, and mouse beta-cells demonstrate that the binding of a fluorescent derivative of ryanodine (BODIPY FL-X ryanodine) to its receptors is specific, reversible, and of high affinity. Rat islets and BTC3 insulinoma cells are shown by reverse transcriptase polymerase chain reaction analyses to express mRNA corresponding to the type 2 isoform of ryanodine receptor-intracellular Ca2+ release channel (RYR2). Single-cell measurements of [Ca2+]i using primary cultures of rat and human beta-cells indicate that GLP-1 facilitates Ca2+-induced Ca2+ release (CICR), whereby mobilization of Ca2+ stores is triggered by influx of Ca2+ through L-type Ca2+ channels. In these cells, GLP-1 is shown to interact with metabolism of D-glucose to produce a fast transient increase of [Ca2+]i. This effect is reproduced by 8-Br-cAMP, but is blocked by a GLP-1 receptor antagonist (exendin-(9-39)), a cAMP antagonist ((Rp)-cAMPS), an L-type Ca2+ channel antagonist (nimodipine), an antagonist of the sarco(endo)plasmic reticulum Ca2+ ATPase (thapsigargin), or by ryanodine. Characterization of the CICR mechanism by voltage clamp analysis also demonstrates a stimulation of Ca2+ release by caffeine. These findings provide new support for a model of beta-cell signal transduction whereby GLP-1 promotes CICR by sensitizing intracellular Ca2+ release channels to the stimulatory influence of cytosolic Ca2+.
胰高血糖素样肽-1(GLP-1)是一种由肠道产生的促胰岛素激素,目前正作为一种新型治疗药物用于2型糖尿病的治疗研究。对朗格汉斯胰岛的体外研究表明,GLP-1与特定的β细胞G蛋白偶联受体相互作用,从而通过提高细胞内cAMP和Ca2+水平促进胰岛素胞吐作用。在此我们报告,GLP-1对Ca2+信号的刺激作用部分源于cAMP依赖性的ryanodine敏感性Ca2+储存库的动员。对人、大鼠和小鼠β细胞的研究表明,ryanodine的荧光衍生物(BODIPY FL-X ryanodine)与其受体的结合具有特异性、可逆性且亲和力高。逆转录聚合酶链反应分析显示,大鼠胰岛和BTC3胰岛素瘤细胞表达与ryanodine受体-细胞内Ca2+释放通道(RYR2)的2型同工型相对应的mRNA。使用大鼠和人β细胞原代培养物对[Ca2+]i进行的单细胞测量表明,GLP-1促进Ca2+诱导的Ca2+释放(CICR),即Ca2+储存库的动员是由Ca2+通过L型Ca2+通道内流触发的。在这些细胞中,GLP-1被证明与D-葡萄糖代谢相互作用,导致[Ca2+]i快速短暂升高。8-Br-cAMP可重现这种效应,但被GLP-1受体拮抗剂(艾塞那肽-(9-39))、cAMP拮抗剂((Rp)-cAMPS)、L型Ca2+通道拮抗剂(尼莫地平)、肌浆网Ca2+ ATP酶拮抗剂(毒胡萝卜素)或ryanodine阻断。通过电压钳分析对CICR机制的表征也表明咖啡因可刺激Ca2+释放。这些发现为β细胞信号转导模型提供了新的支持,即GLP-1通过使细胞内Ca2+释放通道对胞质Ca2+的刺激作用敏感化来促进CICR。